What would you like to look for?
Site search
14 November 2023

Nouscom AG, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate of re-nowned international healthcare investors.

The Series C round was co-led by Andera Partners, Bpifrance (through its InnoBio 2 fund) and M Ventures, with participation from Revelation Partners, Indaco Venture Partners, Panakès Part-ners, XGen Ventures, and other undisclosed investors together with continued support from exist-ing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline.

VISCHER acted as legal advisor to Nouscom in the transaction. The VISCHER team includes Matthias Staehelin (Partner, Corporate / M&A), Adrian Briner (Managing Associate, Tax), Pauline Pfirter (Senior Associate, Corporate / M&A) and Luzius Zumstein (Managing Associate, Corporate / M&A).